India Pharma 2019 & India Medical Device 2019 Inaugurated;
Theme: Enabling Quality Affordable Healthcare & Accelerating Growth to Achieve Universal Healthcare
Government taking measures to help Indian pharmaceutical sector become Rs. 3 lakh crore market: Mansukh Mandaviya
Steps afoot to make pharmaceuticals a Rs 3 lakh crore market
- Opportunity for Industry through Ayushman Bharat Programme
- Technologies like AI and advanced analytics being increasingly adopted by pharmaceutical industry: FICCI-KPMG Knowledge Paper
BANGALORE, 18 February 2019:
“While India continues to maintain leadership position in manufacturing and supply of high quality generic medicines, the Government’s focus is on improving access to affordable healthcare for all and contribute to the largest Government-funded healthcare programme in the world, Ayushman Bharat”, said Union Minister of Chemicals and Fertilizers, Statistics and Programme Implementation, D.V. Sadananda Gowda, while inaugurating the 4th edition of India’s biggest Global Conference on Pharmaceuticals and Medical Devices, in Bengaluru today.
Mr D V Sadananda Gowda, Minister of Chemicals and Fertilizer, Statistical and Programme Implementation, Government of India, said here today that the Government’s focus was on improving access to affordable medical care and contribute to the National Health Protection Scheme, even as India continues to maintain its leadership position in manufacturing and supply of high quality generic medicines.
In his address, Gowda remembered the late Union Cabinet Minister Ananthkumar for his vision to bring all stakeholders of pharma and medical devices industry on one platform through this conference and to help the Government to bring policy changes for removing roadblocks by addressing the pressing issues in this sector. The Government continues to strive to increase the ease of doing business in India through such initiatives.
The Minister said that India continues to maintain its leadership position in manufacturing and supply of high quality generic medicines. With several proactive measures by the Government, exports have improved and the growth in Pharma sector is back on track. The Pharma industry is expected to grow at a CAGR of 15% in the near future. On the other hand, as per industry estimates, the medical devices market is expected to grow to $50 billion by 2025, he added.
Addressing the inaugural session, Mandaviya stressed on the commendable work the Government is doing to ensure affordable healthcare for all through initiatives like Ayushman Bharat. He said that the Government is taking measures to help Indian pharmaceutical sector become a Rs. 3 lakh crore market, making it a global player. The Minister further said that the Government has taken a number of steps to boost the indigenous API industry growth in India. These include constituting a Task Force containing all stakeholders to study the issues of APIs and chart out a strategy to boost their indigenous manufacturing; giving thrust to cluster based development of API industry; in principle approval to 2 API parks, one each in Assam and Andhra Pradesh, among others.
Mr Mansukh L. Mandaviya, Minister of State for Chemicals & Fertilizers, Road Transport and Highways, Shipping, Government of India, while stressing on the development of infrastructure and affordable healthcare through initiatives like Ayushman Bharat, said that the Government was taking measures to make the Indian pharmaceutical sector a Rs. 3 lakh crore market.
Mr K J George, Minister for Large & Medium Scale Industries, Government of Karnataka, said that the state government plans to set up a special pharmaceuticals SEZ in Hassan and Pharma Parks in Bengaluru and Mangalore, which forms a part of the Government of India’s aim of investing over USD 50 billion by 2025.
Dr Henk Bekedam, WHO Representative to India, stated that considering the increased involvement of the Micro, Small & Medium Enterprises in the medical devices manufacturing sector, WHO will provide technical support to the sector to upgrade manufacturing standards.
Mr S Sridhar, Chairman, FICCI Pharma Committee said that industry believed in universal healthcare at affordable price for all Indian citizens, adding that this is a long term plan and requires a joint effort of the Government, industry and other stakeholders to collectively own this vision.
Mr Badhri Iyengar, Chairman, FICCI Medical Device Forum, said that it was important to look at having a unified healthcare regulator which could act as a bridge between the industry and the Government to create one window for facilitating business.
The Union Minister for Statistics & Programme Implementation and Chemicals & Fertilizers, D.V. Sadananda Gowda presenting an Award, at the inaugural ceremony of the “India Pharma- 2019 and India Medical Device -2019”, in Bangalore on February 18, 2019. The Minister of State for Road Transport & Highways, Shipping and Chemicals & Fertilizers, Mansukh L. Mandaviya, the Secretary, Department of Pharmaceuticals, J.P. Prakash and other dignitaries are also seen.
Drug regulators from over 30 countries including Russia, Kenya, the UK, Malaysia, Indonesia, Saudi Arabia & Uzbekistan participated in the event. The event also saw participation of drug regulators from 15 states across India.
A FICCI-KPMG Knowledge Paper “Evolution to revolution: by use of Artificial Intelligence and Advanced Analytics in pharma” was also released at the event.
| Highlights of FICCI-KPMG Knowledge Paper “Evolution to revolution: by use of Artificial Intelligence and Advanced Analytics in pharma”
· Catalyzed by an exciting range of new, disruptive technologies, the pharmaceutical industry needs to reimagine its future. And the need to reimagine is being driven by shifts which are disturbing the industry’s status quo – pressure to reduce costs and demonstrate greater value, swing from treatment to prevention, and personalized treatments. These shifts are challenging the overall business model of the pharmaceutical companies · Emerging technologies, AI and advanced analytics are being increasingly adopted by the pharmaceutical industry in many diverse and interesting ways · The value of technologies come from their ability to process large amount of complex, both structured and unstructured data, at a rapid pace to generate actionable insights and thereby reduce costs, improve time to market and gain competitive strength in the market place · While lot of interesting applications are in areas related to drug discovery, applications in other areas such as drug dosage and safety, manufacturing and supply chain and commercialization is being further explored · As far as technologies are concerned, pharmaceutical companies are choosing their fields of play and also who they play with, with a growing emphasis on collaboration and partnership. Accordingly, the industry is witnessing many such partnerships and quite often with technology start-ups |
